{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:09:19Z","timestamp":1772816959079,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":547,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.exphem.2023.09.001","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:13:06Z","timestamp":1695341586000},"page":"59-69.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Inhibition of PAK1 generates an ameliorative effect on MPLW515L mouse model of myeloproliferative neoplasms by regulating the differentiation and survival of megakaryocytes"],"prefix":"10.1016","volume":"127","author":[{"given":"Chunling","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shujin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangru","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qigang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2023.09.001_bib0001","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","article-title":"Myeloproliferative neoplasm stem cells","volume":"129","author":"Mead","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.09.001_bib0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2023.09.001_bib0003","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.09.001_bib0004","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2023.09.001_bib0005","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.exphem.2023.09.001_bib0006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s13577-014-0102-2","article-title":"BMS-777607 promotes megakaryocytic differentiation and induces polyploidization in the CHRF-288-11 cells","volume":"28","author":"Nurhayati","year":"2015","journal-title":"Hum Cell"},{"key":"10.1016\/j.exphem.2023.09.001_bib0007","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cell.2012.06.032","article-title":"Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL","volume":"150","author":"Wen","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2023.09.001_bib0008","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41375-018-0224-8","article-title":"AKT activation is a feature of CALR mutant myeloproliferative neoplasms","volume":"33","author":"Fu","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.09.001_bib0009","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.3995","article-title":"Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition","volume":"21","author":"Wen","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2023.09.001_bib0010","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","article-title":"Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial","volume":"25","author":"Gangat","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2023.09.001_bib0011","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.cellsig.2014.04.020","article-title":"P21-activated kinase in inflammatory and cardiovascular disease","volume":"26","author":"Taglieri","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.exphem.2023.09.001_bib0012","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1042\/BST20160134","article-title":"Targeting PAK1","volume":"45","author":"Semenova","year":"2017","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.exphem.2023.09.001_bib0013","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1038\/ncomms8437","article-title":"Cdk1 phosphorylates the Rac activator Tiam1 to activate centrosomal PAK and promote mitotic spindle formation","volume":"6","author":"Whalley","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2023.09.001_bib0014","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1080\/14728222.2016.1239719","article-title":"Targeting p21 activated kinase 1 (Pak1) to PAKup pancreatic cancer","volume":"20","author":"Jagadeeshan","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.exphem.2023.09.001_bib0015","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1002\/ctm2.191","article-title":"The metastatic promoter DEPDC1B induces epithelial-mesenchymal transition and promotes prostate cancer cell proliferation via Rac1-PAK1 signaling","volume":"10","author":"Li","year":"2020","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.exphem.2023.09.001_bib0016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12964-019-0446-z","article-title":"Targeting PKCiota-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma","volume":"17","author":"Ito","year":"2019","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.exphem.2023.09.001_bib0017","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41417-020-00215-2","article-title":"circSFMBT1 promotes pancreatic cancer growth and metastasis via targeting miR-330-5p\/PAK1 axis","volume":"28","author":"Xu","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.exphem.2023.09.001_bib0018","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4161\/cl.21882","article-title":"PAK signaling in cancer","volume":"2","author":"Ye","year":"2012","journal-title":"Cell Logist"},{"key":"10.1016\/j.exphem.2023.09.001_bib0019","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.gene.2016.12.014","article-title":"Structure, biochemistry, and biology of PAK kinases","volume":"605","author":"Kumar","year":"2017","journal-title":"Gene"},{"key":"10.1016\/j.exphem.2023.09.001_bib0020","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/cancers11101527","article-title":"The PAK1-Stat3 signaling pathway activates IL-6 gene transcription and human breast cancer stem cell formation","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.exphem.2023.09.001_bib0021","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1182\/blood-2014-12-618801","article-title":"PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome","volume":"126","author":"Pandolfi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.09.001_bib0022","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1134\/S002689332003019X","article-title":"High Expression Level of SP1, CSF1R, and PAK1 Correlates with Sensitivity of Leukemia Cells to the Antibiotic Mithramycin","volume":"54","author":"Vagapova","year":"2020","journal-title":"Mol Biol (Mosk)"},{"key":"10.1016\/j.exphem.2023.09.001_bib0023","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1182\/blood-2014-10-604504","article-title":"Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization","volume":"125","author":"Kosoff","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.09.001_bib0024","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10549-019-05329-2","article-title":"Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer","volume":"177","author":"Korobeynikov","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.exphem.2023.09.001_bib0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.molcel.2005.08.035","article-title":"The GIT-associated kinase PAK targets to the centrosome and regulates Aurora-A","volume":"20","author":"Zhao","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2023.09.001_bib0026","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1182\/blood-2014-12-615401","article-title":"Aurora kinase A is required for hematopoiesis but is dispensable for murine megakaryocyte endomitosis and differentiation","volume":"125","author":"Goldenson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2023.09.001_bib0027","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.3390\/ijms21207531","article-title":"PAK1 regulates MEC-17 acetyltransferase activity and microtubule acetylation during proplatelet extension","volume":"21","author":"van Dijk","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2023.09.001_bib0028","first-page":"499","article-title":"Blocking PAK1 kinase activity promotes the differentiation of acute megakaryocytic leukemia cells and induces their apoptosis","volume":"43","author":"Wang","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.exphem.2023.09.001_bib0029","first-page":"852","article-title":"The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model","volume":"119","author":"Mercher","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2023.09.001_bib0030","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1158\/0008-5472.CAN-12-2246","article-title":"p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model","volume":"72","author":"Chow","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2023.09.001_bib0031","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.chembiol.2008.03.005","article-title":"An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase","volume":"15","author":"Deacon","year":"2008","journal-title":"Chem Biol"},{"key":"10.1016\/j.exphem.2023.09.001_bib0032","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/leu.2016.323","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"31","author":"Harrison","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.09.001_bib0033","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2023.09.001_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2023.09.001_bib0035","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in myelofibrosis","volume":"4","author":"Mullally","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2023.09.001_bib0036","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1021\/acsmedchemlett.5b00398","article-title":"Design of selective PAK1 inhibitor G-5555: improving properties by employing an unorthodox low-pK a polar moiety","volume":"6","author":"Ndubaku","year":"2015","journal-title":"ACS Med Chem Lett"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X23017010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X23017010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:39:06Z","timestamp":1759567146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X23017010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":36,"alternative-id":["S0301472X23017010"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2023.09.001","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of PAK1 generates an ameliorative effect on MPLW515L mouse model of myeloproliferative neoplasms by regulating the differentiation and survival of megakaryocytes","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2023.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 ISEH \u2013 Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}